Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease
Shahid M. Malik, Jawad Ahmad – 15 January 2010
Successful endoscopic treatment of biliary cast syndrome in an orthotopic liver transplant patient with a Roux‐en‐Y anastomosis via balloon enteroscopy
Atif Saleem, Todd H. Baron – 15 January 2010
Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha‐2b
Elizabeth B. Haagsma, Annelies Riezebos‐Brilman, Arie P. van den Berg, Robert J. Porte, Hubert G. M. Niesters – 15 January 2010 – Hepatitis E virus (HEV) infections are known to run a self‐limiting course. Recently, chronic hepatitis E has been described in immunosuppressed patients after solid‐organ transplantation. Besides the general recommendation to lower the immunosuppressive medication in these patients, there is currently no specific treatment.
Tumor recurrence following liver transplantation for hepatocellular carcinoma: Role of tumor proliferation status
Aileen E. Marshall, Simon M. Rushbrook, Sarah L. Vowler, Christopher R. Palmer, R. Justin Davies, Paul Gibbs, Susan E. Davies, Nicholas Coleman, Graeme J. M. Alexander – 12 January 2010 – The selection of patients with hepatocellular carcinoma for liver transplantation is currently based on the size and number of tumors to minimize the risk of recurrence. These criteria measure tumor bulk but may not reflect tumor behavior accurately. A biological marker of tumor behavior could aid with patient selection further.
Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody–positive donors: A systematic review
Sammy Saab, Benjamin Waterman, Amanda C. Chi, Myron J. Tong – 12 January 2010 – Orthotopic liver transplantation (OLT) recipients without hepatitis B virus (HBV) infection who receive liver grafts from antibody to hepatitis B core antigen–positive [HBcAb(+)], hepatitis B surface antigen–negative [HBsAg(−)] donors have an increased risk of developing de novo hepatitis B infection.
Acute and long‐term effects of inhaled iloprost in portopulmonary hypertension
Maria Teresa Melgosa, Giovanni L. Ricci, Juan Carlos García‐Pagan, Isabel Blanco, Pilar Escribano, Juan G. Abraldes, Josep Roca, Jaume Bosch, Joan Albert Barberà – 12 January 2010 – Portopulmonary hypertension (PoPH) is a serious condition without an established treatment. Drugs used to treat pulmonary hypertension may have detrimental effects on portal hypertension. This study was designed to assess in patients with PoPH the acute effects of inhaled iloprost (iILO) on pulmonary and hepatic hemodynamics and to evaluate the clinical outcome after 12 months of treatment.
Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: An intention‐to‐treat analysis
Omar Barakat, R. Patrick Wood, Claire F. Ozaki, Victor Ankoma‐Sey, Joseph Galati, Mark Skolkin, Barry Toombs, Mary Round, Warren Moore, Luis Mieles – 12 January 2010 – In selected patients, locoregional therapy (LRT) has been successful in downstaging advanced hepatocellular carcinoma (HCC) so that the conventional criteria for liver transplantation (LT) can be met. However, the factors that predict successful treatment are largely unidentified. To determine these factors, we analyzed our experience with multimodal LRT in downstaging advanced HCC before LT in a retrospective cohort study.
Strategy to prevent recurrent portal vein stenosis following interventional radiology in pediatric liver transplantation
Yukihiro Sanada, Youichi Kawano, Koichi Mizuta, Satoshi Egami, Makoto Hayashida, Taiichi Wakiya, Takehito Fujiwara, Yasunaru Sakuma, Masanobu Hydo, Manabu Nakata, Yoshikazu Yasuda, Hideo Kawarasaki – 12 January 2010 – Portal vein complications after liver transplantation (LT) are serious complications that can lead to graft liver failure. Although the treatment of interventional radiology (IVR) by means of balloon dilatation for portal vein stenosis (PVS) after LT is an effective method, the high rate of recurrent PVS is an agonizing problem.
Splanchnic hemodynamics in liver regeneration after right liver living donor liver transplantation
See Ching Chan, Chung Mau Lo, Sheung Tat Fan – 12 January 2010
Liver transplantation and combined liver‐heart transplantation in patients with familial amyloid polyneuropathy: A single‐center experience
Ana‐Paula Barreiros, Felix Post, Maria Hoppe‐Lotichius, Reinhold P. Linke, Christian F. Vahl, Hans‐Joachim Schäfers, Peter R. Galle, Gerd Otto – 12 January 2010 – Liver transplantation (LT) is the only curative option for patients with familial amyloid polyneuropathy (FAP) at present. Twenty patients with FAP underwent LT between May 1998 and June 2007. Transthyretin mutations included predominantly the Val30Met mutation but also 10 other mutations.